Role of Biphasic Changes in Splenic Dendritic Cell Activity in a Mouse Model of Multiple Organ Dysfunction Syndrome

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2014 Sep 9

PMID 25197343

Authors

Yi Lv

Qian Liu

Min Zhao

Yiduo Jin

Jiangyang Lu

Affiliations

Soon will be listed here.

Abstract

To analyze the changes in splenic dendritic cell (DC) activity and serum cytokine levels during the progression of multiple organ dysfunction syndrome (MODS). A C57BL/6 mouse model of MODS was established by intraperitoneal injection of zymosan. Immunohistochemistry and flow cytometry were used to detect expression of I-A(b) (MHC-II molecules of mice) as well as co-stimulatory and co-inhibitory molecules in spleen and DC surface. The levels of various cytokines in serum and spleen tissue were analyzed 6 h, 12 h, 24 h, 48 h, 5 d and 12 d after injury. Death occurred at 24-48 h and 10-12 d after injury. The expression of I-A(b) and CD86 in spleen tissue and on DCs increased 6-12 h after injury, followed by gradual reduction and at 12 d. The inhibitory molecule, PD-L1, was expressed on normal DCs, but expression of PD-1 was undetectable. PD-L1 and PD-1 expression increased and remained high at 5 d and 12 d after injury. In addition, TNF and IL-1 levels increased 6-12 h after injury; HMGB1 and IL-10 levels increased 24 h and 5 d after injury, respectively. In contrast, IL-2 and IL-12 decreased with disease progression. At 12 d after injury, proinflammatory and anti-inflammatory cytokine levels remained high, while IL-2 and IL-12 were significantly reduced. IL-10 and IL-12 changes in spleen were consistent with those in serum. MODS progression was characterized by changes in splenic DC activity as well as altered serum pro-inflammatory and anti-inflammatory cytokine levels, suggesting early immune activation and predominant immune tolerance at the late stage.

References

Hotchkiss R, Monneret G, Payen D . Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013; 13(3):260-8. PMC: 3798159. DOI: 10.1016/S1473-3099(13)70001-X. View

Banchereau J, Steinman R . Dendritic cells and the control of immunity. Nature. 1998; 392(6673):245-52. DOI: 10.1038/32588. View

Sweeney D, Danner R, Eichacker P, Natanson C . Once is not enough: clinical trials in sepsis. Intensive Care Med. 2008; 34(11):1955-60. DOI: 10.1007/s00134-008-1274-6. View

Huston J, Ochani M, Rosas-Ballina M, Liao H, Ochani K, Pavlov V . Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis. J Exp Med. 2006; 203(7):1623-8. PMC: 2118357. DOI: 10.1084/jem.20052362. View

Volman T, Hendriks T, Goris R . Zymosan-induced generalized inflammation: experimental studies into mechanisms leading to multiple organ dysfunction syndrome. Shock. 2005; 23(4):291-7. DOI: 10.1097/01.shk.0000155350.95435.28. View

Ward N, Casserly B, Ayala A . The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med. 2008; 29(4):617-25, viii. PMC: 2786900. DOI: 10.1016/j.ccm.2008.06.010. View

Wheeler D, Zingarelli B, Wheeler W, Wong H . Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response. Recent Pat Inflamm Allergy Drug Discov. 2009; 3(2):96-112. PMC: 2754156. DOI: 10.2174/187221309788489779. View

Chen C, Qu Q, Huang J, Zhu Y, Ge Y, Wang Q . Expression of programmed-death receptor ligands 1 and 2 may contribute to the poor stimulatory potential of murine immature dendritic cells. Immunobiology. 2007; 212(3):159-65. DOI: 10.1016/j.imbio.2007.01.004. View

de Heusch M, Oldenhove G, Urbain J, Thielemans K, Maliszewski C, Leo O . Depending on their maturation state, splenic dendritic cells induce the differentiation of CD4(+) T lymphocytes into memory and/or effector cells in vivo. Eur J Immunol. 2004; 34(7):1861-9. DOI: 10.1002/eji.200424878. View

10.

Marshall J . Sepsis: rethinking the approach to clinical research. J Leukoc Biol. 2008; 83(3):471-82. DOI: 10.1189/jlb.0607380. View

11.

Kollef K, Schramm G, Wills A, Reichley R, Micek S, Kollef M . Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest. 2008; 134(2):281-287. DOI: 10.1378/chest.08-1116. View

12.

Riedemann N, Guo R, Ward P . The enigma of sepsis. J Clin Invest. 2003; 112(4):460-7. PMC: 171398. DOI: 10.1172/JCI19523. View

13.

Dong H, Zhu G, Tamada K, Chen L . B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999; 5(12):1365-9. DOI: 10.1038/70932. View

14.

Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu Y . Immunobiology of dendritic cells. Annu Rev Immunol. 2000; 18:767-811. DOI: 10.1146/annurev.immunol.18.1.767. View

15.

Liao W, Lin J, Leonard W . Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity. 2013; 38(1):13-25. PMC: 3610532. DOI: 10.1016/j.immuni.2013.01.004. View

16.

Adib-Conquy M, Cavaillon J . Compensatory anti-inflammatory response syndrome. Thromb Haemost. 2009; 101(1):36-47. View

17.

Borovikova L, Ivanova S, Zhang M, Yang H, Botchkina G, Watkins L . Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000; 405(6785):458-62. DOI: 10.1038/35013070. View

18.

Sato K, Yamashita N, Baba M, Matsuyama T . Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood. 2003; 101(9):3581-9. DOI: 10.1182/blood-2002-09-2712. View

19.

Vincent J, Sun Q, Dubois M . Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis. 2002; 34(8):1084-93. DOI: 10.1086/339549. View

20.

Limaye A, Kirby K, Rubenfeld G, Leisenring W, Bulger E, Neff M . Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA. 2008; 300(4):413-22. PMC: 2774501. DOI: 10.1001/jama.300.4.413. View